M., Cohen, J
see the NHS orlistat page for eligibility and guidance), or GLP-1-based therapies such as semaglutide 2.4 mg (Wegovy), which has received MHRA approval and a NICE Technology Appraisal recommendation (NICE TA875) for use in adults with a BMI of 35 kg/m or above (or 3034.9 kg/m in certain circumstances) alongside at least one weight-related comorbidity, when used within a specialist weight management service Enquire about clinical trial eligibility , if you are interested in accessing investigational medicines through a regulated research pathway your GP or specialist can advise, and you can search for trials via the NIHR 'Be Part of Research' website or ClinicalTrials.gov Discuss realistic expectations , as even the most effective weight loss medicines work best alongside dietary changes, increased physical activity, and behavioural support Your GP can refer you to a specialist weight management service if appropriate
CPR: Cytochrome P450 reductase
These can increase urination and contribute to dehydration
Heres what sets our program apart: Medical Oversight : Youll have regular check-ins with our experienced providers to monitor your progress and adjust your dosage as needed
We aim to create an environment where you can feel heard, understood, and free to express yourself without judgment
